Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by CASHEAGLEon Dec 12, 2021 1:59pm
106 Views
Post# 34223170

RE:Wow!!! That's A Bullrun Soapbox Story For The Ages !!!

RE:Wow!!! That's A Bullrun Soapbox Story For The Ages !!!Your post is all assumption based on no facts.

Please provide evidence of your statement Breathtec Biomedical walked away from the deal with absolutely nothing to show for it's collaborative efforts with Cannabix Technologies. Not even a stake in shares. Ironically, Cannabix Technologies holds shares of Breathtec Biomedical. Cannabix has royally screwed Breathtec Biomedical and the management team of Breathtec Biomedical is intertwined with Cannabix Technologies for the outset to the present.

University of Florida did not licence the technology for drug detection alone. They wanted two companies to do it, Breathtec found it very difficult to detect disease in breath and dropped the option. Cannabix was licenced by UFL for Drug Detection and Breathec was disease..two totally different technologies and fields of licence. There were zero sharing of costs and Breathec never paid Cannabix a dime or issued Cannabix shares. You statements are 110% fabricated lies.

Your statements are uneducated, biased and not fact based. Why are you here on thes companies if you dont like the teams here. As stated Growmax was a simple investor in AGN and free to sell its shares like any other investor has the right to do so. What rule states that a Founder related entity is only able to provide investments into that entity but never sell? Your business acumen seems asinine and its no wonder you are probably sucking wind investing in deals at the height and then blaming management for your lack of investing skills. Get a life and stop trying to run these companies on these bullboards with your childish dribble and made up lies. Post some evidence to support you pulled from the air claims
<< Previous
Bullboard Posts
Next >>